Literature DB >> 25306251

Dysnatremia, vasopressin, atrial natriuretic peptide and mortality in patients with community-acquired pneumonia: results from the german competence network CAPNETZ.

Stefan Krüger1, Santiago Ewig2, Sven Giersdorf3, Oliver Hartmann3, Dirk Frechen1, Gernot Rohde4, Norbert Suttorp5, Tobias Welte6.   

Abstract

BACKGROUND: Dysnatremia is a frequent finding in patients with community acquired pneumonia (CAP) and a predictor of mortality. We studied the relation between dysnatremia, comorbidities and CT-pro-AVP and MR-proANP.
METHODS: We enrolled 2138 patients (60 ± 18 years, 55% male) with CAP from the CAPNETZ database. Pro-atrial natriuretic peptide (proANP), pro-vasopressin (proAVP), serum sodium and CRB-65 score were determined on admission. Patients were followed up for 28 days. Sodium concentration on admission was examined as a function of mortality at 28 days. Hyponatremia (HypoN) was defined as admission serum sodium <136 mmol/L, hypernatremia (HyperN) as admission serum sodium >145 mmol/L.
RESULTS: HypoN was diagnosed in 680 (31.8%) patients, HyperN in 29 (1.4%) patients. Comorbidities were associated with sodium levels, and CT-pro-AVP and MR-proANP were inversely related to sodium levels. Patients with HypoN were older, had a higher CRB-65 score and higher values of CT-proAVP and MR-proANP (all p < 0.05). When examined as a function of sodium values, a U-shaped association was found between sodium levels and 28 day mortality. In multivariate Cox proportional hazards analysis, HypoN and HyperN were independent predictors of 28 day mortality. Sodium levels added to the predictive potential of proAVP and proANP.
CONCLUSION: HypoN is common at admission among CAP patients and is independently associated with mortality. HyperN is rare at admission among CAP patients but is also independently associated with mortality. The combination of sodium and CT-pro-AVP and MR-proANP levels achieved the highest prediction of mortality.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Community acquired pneumonia; Hyponatremia; Prognosis; Vasopressin

Mesh:

Substances:

Year:  2014        PMID: 25306251     DOI: 10.1016/j.rmed.2014.09.014

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  15 in total

1.  Novel Vasoregulatory Aspects of Hereditary Angioedema: the Role of Arginine Vasopressin, Adrenomedullin and Endothelin-1.

Authors:  Erika Kajdácsi; Péter K Jani; Dorottya Csuka; Lilian Varga; Zoltán Prohászka; Henriette Farkas; László Cervenak
Journal:  J Clin Immunol       Date:  2016-02-12       Impact factor: 8.317

2.  Inverse relationship between IL-6 and sodium levels in patients with COVID-19 and other respiratory tract infections: data from the COVIVA study.

Authors:  Cihan Atila; Sophie Monnerat; Roland Bingisser; Martin Siegemund; Maurin Lampart; Marco Rueegg; Núria Zellweger; Stefan Osswald; Katharina Rentsch; Mirjam Christ-Crain; Raphael Twerenbold
Journal:  Endocr Connect       Date:  2022-09-26       Impact factor: 3.221

3.  Severe Hyponatremia due to Levofloxacin Treatment for Pseudomonas aeruginosa Community-Acquired Pneumonia in a Patient with Oropharyngeal Cancer.

Authors:  Mihaela Mocan; Sorin Nicu Blaga
Journal:  Case Rep Med       Date:  2016-10-25

4.  Sodium variability is associated with increased mortality in severe burn injury.

Authors:  Soman Sen; Nam Tran; Brian Chan; Tina L Palmieri; David G Greenhalgh; Kiho Cho
Journal:  Burns Trauma       Date:  2017-11-06

Review 5.  Hyponatremia in Infectious Diseases-A Literature Review.

Authors:  Anna L Królicka; Adrianna Kruczkowska; Magdalena Krajewska; Mariusz A Kusztal
Journal:  Int J Environ Res Public Health       Date:  2020-07-23       Impact factor: 3.390

6.  Prognostic Impact of Hyponatremia and Hypernatremia in COVID-19 Pneumonia. A HOPE-COVID-19 (Health Outcome Predictive Evaluation for COVID-19) Registry Analysis.

Authors:  Jorge Gabriel Ruiz-Sánchez; Ivan J Núñez-Gil; Martin Cuesta; Miguel A Rubio; Charbel Maroun-Eid; Ramón Arroyo-Espliguero; Rodolfo Romero; Victor Manuel Becerra-Muñoz; Aitor Uribarri; Gisela Feltes; Daniela Trabattoni; María Molina; Marcos García Aguado; Martino Pepe; Enrico Cerrato; Emilio Alfonso; Alex Fernando Castro Mejía; Sergio Raposeiras Roubin; Luis Buzón; Elvira Bondia; Francisco Marin; Javier López Pais; Mohammad Abumayyaleh; Fabrizio D'Ascenzo; Elisa Rondano; Jia Huang; Cristina Fernandez-Perez; Carlos Macaya; Paz de Miguel Novoa; Alfonso L Calle-Pascual; Vicente Estrada Perez; Isabelle Runkle
Journal:  Front Endocrinol (Lausanne)       Date:  2020-11-30       Impact factor: 5.555

7.  Dysnatremia is a Predictor for Morbidity and Mortality in Hospitalized Patients with COVID-19.

Authors:  Ploutarchos Tzoulis; Julian A Waung; Emmanouil Bagkeris; Ziad Hussein; Aiyappa Biddanda; John Cousins; Alice Dewsnip; Kanoyin Falayi; Will McCaughran; Chloe Mullins; Ammara Naeem; Muna Nwokolo; Helen Quah; Syed Bitat; Eithar Deyab; Swarupini Ponnampalam; Pierre-Marc Bouloux; Hugh Montgomery; Stephanie E Baldeweg
Journal:  J Clin Endocrinol Metab       Date:  2021-05-13       Impact factor: 5.958

8.  Hypochloraemia as a predictor of developing hyponatraemia and poor outcome in acute heart failure patients.

Authors:  Bojana Radulović; Ines Potočnjak; Sanda Dokoza Terešak; Matias Trbušić; Nada Vrkić; Davorin Malogorski; Neven Starčević; Milan Milošević; Saša Frank; Vesna Degoricija
Journal:  Int J Cardiol       Date:  2016-03-22       Impact factor: 4.164

Review 9.  Advances in the prevention, management, and treatment of community-acquired pneumonia.

Authors:  Mathias W Pletz; Gernot G Rohde; Tobias Welte; Martin Kolditz; Sebastian Ott
Journal:  F1000Res       Date:  2016-03-08

10.  Prevalence and Impact of Hyponatremia in Patients With Coronavirus Disease 2019 in New York City.

Authors:  Jennifer A Frontera; Eduard Valdes; Joshua Huang; Ariane Lewis; Aaron S Lord; Ting Zhou; D Ethan Kahn; Kara Melmed; Barry M Czeisler; Shadi Yaghi; Erica Scher; Thomas Wisniewski; Laura Balcer; Elizabeth Hammer
Journal:  Crit Care Med       Date:  2020-12       Impact factor: 9.296

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.